NDAINTRAVESICALSOLUTION
Approved
Apr 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
CYSTO-CONRAY II (iothalamate meglumine) by Guerbet is clinical pharmacology the most important characteristic of contrast media is the iodine content. First approved in 1972.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYSTO-CONRAY II is an iothalamate meglumine contrast media administered intravesically for retrograde urography to visualize the lower urinary tract. The drug relies on iodine's high atomic weight to provide radiodensity for radiographic imaging. Systemic absorption is typically minimal (<1%) but can reach 12% with pyelorenal backflow, potentially causing iodine-mediated thyrotropic effects.
LOE Approaching
Product is in late-stage lifecycle with limited commercial expansion opportunities; brand team likely focused on market defense and operational efficiency rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY The most important characteristic of contrast media is the iodine content. The relatively high atomic weight of iodine contributes sufficient radiodensity for radiographic contrast. Following instillation by sterile catheter, Cysto-Conray II provides for visualization of the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CYSTO-CONRAY II offers limited career growth opportunities given its LOE-approaching status and zero linked job postings; roles are maintenance-focused rather than high-visibility brand building. Career value lies in specialized regulatory, compliance, and operational expertise within legacy pharmaceutical portfolios.
Regulatory Affairs Specialist
Worked on CYSTO-CONRAY II at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.